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ABSTRACT
Activation of adenosine receptors (ARs) has been implicated in
the modulation of renal and cardiovascular systems, as well as
erectile functions. Recent studies suggest that adenosine-
mediated regulation of erectile function is mainly mediated
through A2BAR activation. However, no studies have been
conducted to determine the contribution of AR subtype in
the regulation of the vascular tone of the pudendal artery (PA),
the major artery supplying and controlling blood flow to the
penis. Our aim was to characterize the contribution of AR
subtypes and identify signaling mechanisms involved in
adenosine-mediated vascular tone regulation in the PA. We
used a DMT wire myograph for muscle tension measurements in
isolated PAs from wild-type, A2AAR knockout, A2BAR knock-
out, and A2A/A2BAR double-knockout mice. Real-time reverse
transcription–polymerase chain reaction was used to determine
the expression of the AR subtypes. Data from our pharmacologic
and genetic approaches suggest that AR activation–mediated
vasodilation in the PA is mediated by both the A2AAR and A2BAR,
whereas neither the A1AR nor A3AR play a role in vascular tone
regulation of the PA. In addition, we showed that A2AAR- and
A2BAR-mediated vasorelaxation requires activation of nitric
oxide and potassium channels; however, only the A2AAR-
mediated response requires protein kinase A activation. Our data
are complemented by mRNA expression showing the expres-
sion of all AR subtypes with the exception of the A3AR. AR
signaling in the PA may play an important role in mediating
erection and represent a promising therapeutic option for the
treatment of erectile dysfunction.
Introduction
Penile erection consists of multiple neurovascular processes
that all simultaneously involve the nerves, blood vessels, and
endothelium in the sinusoids and trabecular smooth muscle
cells of the penis. Those factors, which regulate contraction and
relaxation of vascular smoothmuscle, determine the state of the
penis (flaccidity versus erection) (Andersson, 2001; Tostes et al.,
2007; Nunes et al., 2012). The flaccid state is mainly mediated
by the release of norepinephrine from adrenergic nerve termi-
nals and other vasoconstrictors, such as endothelin-1 and
angiotensin II (Sáenz de Tejada et al., 1989, 2004). The erection
is mainly mediated by nitric oxide (NO) released from the
endothelium and nonadrenergic-noncholinergic nerves in addi-
tion to other neurotransmitters and endothelium-derived
hyperpolarizing factors (EDHFs), such as adenosine (Chiang
et al., 1994; Tostes et al., 2007; Wen et al., 2011b).
Adenosine, a signaling nucleoside, is produced during
conditions of metabolic stress and high cellular activity,
resulting in increased oxygen supply and decreased oxy-
gen consumption. Adenosine is mainly generated by the 59-
nucleotidases CD73 that catalyze the dephosphorylation of
AMP into adenosine. Intracellular adenosine levels are pri-
marily regulated by adenosine kinase, which converts aden-
osine to AMP, whereas extracellular adenosine levels are
critically regulated by adenosine deaminase, which degrades
adenosine to inosine (Blackburn, 2003; Ham and Evans, 2012;
Wen and Xia (2012)). Recently, adenosine was described as
an EDHF because of its ability to relax and hyperpolarize
vascular smooth muscle cells (VSMC) (Ohta et al., 2013). The
activation of adenosine receptors (ARs) is implicated in the
modulation of renal and cardiovascular functions, as well
as erectile function, with both in vivo and in vitro studies
demonstrating that, likeNO, adenosine is a potent vasodilator
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that may regulate penile erection in humans and animals
(Takahashi et al., 1991, 1992; Chiang et al., 1994; Mantelli
et al., 1995; Filippi et al., 2000; Noto et al., 2001; Tostes et al.,
2007; Carneiro et al., 2008; Mi et al., 2008; Vallon and
Osswald, 2009; Phatarpekar et al., 2010; Wen et al., 2010,
2011b, 2012; Ning et al., 2012; Headrick et al., 2013; Layland
et al., 2014). Adenosine binds to a family of four P1 G protein-
coupled AR subtypes: A1, A2A, A2B, and A3. Vascular studies
from our laboratory and others have demonstrated that,
whereas the activation of the A1AR and A3AR results in
vasoconstriction, the activation of the A2AAR and A2BAR
results in vasodilation (Tawfik et al., 2005; Ansari et al.,
2007; Nayeem et al., 2008; El-Awady et al., 2011; Sanjani
et al., 2011; El-Gowelli et al., 2013; Hein et al., 2013; Kunduri
et al., 2013; Teng et al., 2013). The different contribution of
each AR subtype to the physiology or pathophysiology of
erection has been studied in the corpus cavernosum (CC).
Studies in humans and animals reported that both the A2AAR
and A2BAR mediate the CC’s vasorelaxation (Filippi et al.,
2000; Noto et al., 2001; Faria et al., 2006; Tostes et al., 2007;
Mi et al., 2008; Moura et al., 2015). Using quantitative real-
time polymerase chain reaction (qPCR), Mi et al. (2008)
showed that the A2BARwas the predominant receptor subtype
expressed in murine cavernosal smooth muscle cells, whereas
relatively low level expression of the A2AARwas observed. The
subtypes promoting vasoconstriction, namely the A1AR and
A3AR, were not detectable. In contrast, an earlier study by
Tostes et al. (2007) suggested that activation of both the
A2AAR and A2BAR mediate CC relaxation in mice. While the
contribution of the A1AR to erectile function plays an impor-
tant role in the release of neurotransmitters, the role of the
A3AR in erectile function is still not known (Chiang et al.,
1994; Tostes et al., 2007; Ning et al., 2012). Recent studies
demonstrated that adenosine functions to promote penile
erection; however, this research has focused solely on the CC.
In addition to the CC, an important player in regulating
erectile function and blood flow to the penis is the pudendal
artery (PA). The PA is an artery that branches from the
internal iliac artery, providing oxygenated blood to the
external genitals. The PA branches into cavernous arteries
that further branch into tortuous helicine arteries, all feeding
the cavernous sinuses. In the PA, the absence of capillaries
allows for a rapid filling of cavernosal sinuses during erection
(Hale et al., 2009). Recent studies have shown that the PA
contributes approximately 70% of total pudendal-penile vas-
cular resistance, whereas the intrapenile vasculature contrib-
utes less than 25% of total resistance in this bed (Manabe
et al., 2000). In addition, it has been demonstrated that
optimal erection requires vasodilation of both prepenile
arteries, such as the PA, as well as intrapenile arteries
(Manabe et al., 2000; Hale et al., 2009; Hannan et al., 2011).
To date, no studies have characterized the contribution of
adenosine and its receptors in the regulation of the PA vascu-
lar tone. In the present study, we characterized the contribu-
tion of AR subtypes to vascular tone in the PA and identified
signalingmechanisms involved in adenosine-mediated vascular
tone regulation.
Materials and Methods
Animals. The Institutional Animal Care and Use Committee of
West Virginia University approved all experimental protocols. We
followed guidelines set forth by the American Physiologic Society and
National Institutes of Health regarding the care and use of laboratory
animals. A2AAR and A2BAR single knockout (KO) mice (A2AAR KO
and A2BAR KO mice, respectively) were generously provided by
Dr. C. Ledent (Université libre de Bruxelles, Brussels, Belgium) and
Stephen Tilley (University of North Carolina, Chapel Hill, NC),
respectively. A2AAR and A2BAR KO mice, both backcrossed 12
generations to wild-type (WT) C57BL/6 background mice (Jackson
Laboratory, Bar Harbor, ME) were bred to generate A2A/A2BAR
double-KO (DKO) heterozygotes. Double heterozygotes were inter-
crossed, and 1/16 of the offspring were A2A/A2BAR DKO mice. A2A/A2BAR
DKO breeding pairs were then established (Zhou et al., 2014). Mice
were caged on a 12-hour light/dark cycle with free access to standard
chow diet, with water ad libitum.
Muscle Tension Studies in Pudendal Arteries. Mice were
euthanized using sodium pentobarbital (50 mg/kg i.p.). PAs were
excised, transferred into an ice-cold physiologic salt solution (130 mM
NaCl, 14.9 mM NaHCO3, 5.5 mM dextrose, 4.7 mM KCl, 1.18 mM
KH2PO4, 1.17mMMgSO4 × 7H2O, 1.6mMCaCl2 × 2H2O), and dissected
to remove loose connective tissue and fat. The arteries were then cut
into 2-mm segments and mounted on a wire myograph in 5-ml
chambers (DMT, Aarhus, Denmark) containing buffer at 37°C and
continuously bubbled with a mixture of 95% O2 and 5% CO2. The
tissues were stretched to a resting force of 200 mg and allowed to
equilibrate for 60 minutes. Changes in isometric force were recorded
using a PowerLab/8SP data acquisition system (Chart software,
version 5.0; ADInstruments, Colorado Springs, CO). After equilibra-
tion, rings were precontracted with 50 mM KCl to check the contrac-
tility of the individual PA rings. Arterial and endothelial integrity
were assessed by contracting with phenylephrine (Phe, 1026 M),
followed by relaxation with acetylcholine (ACh, 1026 M). Concentration-
response curves (CRC) for AR agonists [59-N-ethylcarboxamidoadenosine
(NECA), 2-chloro-N6-cyclopentyladenosine (CCPA), and 1-[2-chloro-
6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-b-D-
ribofuranuronamide (Cl-IBMECA), 1029 M to 1025 M] were performed.
Endothelium-dependent relaxation was assessed by measuring
the dilatory response to ACh (1029 M to 1025 M) in Phe-contracted
vessels.
Drugs and Solutions. ACh, Phe, NECA, 8-cyclopentyl-1,3-
dipropylxanthine (DPCPX; an A1AR antagonist), KT 5720 [a protein
kinase A (PKA) inhibitor], MRS1523 (an A3AR antagonist), N
G-nitro-
L-arginine methyl ester [L-NAME; a nitric oxide synthase (NOS)
inhibitor], and Cl-IBMECA (an A3AR agonist) were purchased from
Sigma-Aldrich/MilliporeSigma (St. Louis, MO). CCPA (an A1AR
agonist), SCH-58261 (a selective A2AAR antagonist), and CVT-6883
(a selective A2BAR antagonist) were purchased from Tocris Bioscience
(Minneapolis, MN). Stock solutions were prepared in deionized water
or dimethyl sulfoxide (DMSO) and stored in aliquots at –20°C.
Dilutions were prepared immediately before use. Rings were preincu-
bated with antagonist or inhibitors 30 minutes prior to Phe precon-
struction for the CRC. Stock solutions originally diluted in DMSO
were used with a final concentration of less than 0.003% v/v in the
muscle bath; this concentration has been demonstrated to have no
effect on vascular reactivity.
Real-Time Reverse Transcription–Polymerase Chain
Reaction. Total RNA was isolated from PAs of WT mice using an
RNAEasy Total RNA isolation kit from Qiagen (Valencia, CA). This
was followed by conversion of 0.5 mg of total RNA into complemen-
tary DNA (cDNA) using a High Capacity cDNA Archive Kit (Applied
Biosystems, Foster City, CA) according to manufacturer’s instruc-
tions in a total volume of 100 ml. Each sample contained PAs pooled
from seven to nine mice. Because of the relatively low expression
of ARs, a polymerase chain reaction (PCR) PreAmplification Kit
(Applied Biosystems) was used. Reverse transcription–polymerase
chain reaction (qPCR) was performed using an ABI PRISM 7300
Detection System (Applied Biosystems) with TaqMan Universal
Master Mix (Applied Biosystems, Branchburg, NJ) according to
manufacturer’s instructions. The reaction volume (25 ml) included
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12.5 ml of 2 TaqMan Universal Master Mix, 1 ml of cDNA, and 1.25 ml
of 20 FAM-labeled TaqMan Gene Expression Assay Master Mix
solution. For real-time PCR of AR genes, the TaqMan-inventoried gene
expression product was purchased from Applied Biosystems. The 18S
ribosomal RNA was used as an endogenous control. The fold-difference
in expression of target cDNAwas determined using the comparative CT
method. The DCT value was determined in each experiment by
subtracting the average 18S CT value from the corresponding average
CT for the A1, A2A, A2B, and A3AR in coronary arteries, as previously
described (Teng et al., 2013).
Statistical Analysis. Student’s t test was used for the comparison
between two groups, and one-way analysis of variance was used for
groups of three or more. CRC data were analyzed between groups at
the same concentrations. In addition, an F-test was used for the
estimation of EC50 values obtained from best-fit analysis using a
nonlinear, interactive fitting program (GraphPad Prism; Graph Pad
Software Inc. San Diego CA). Data are expressed as means 6 S.E.M.
(N), whereN is the number ofmice. Values ofP, 0.05were considered
a statistically significant difference.
Results
NECA-Mediated Relaxation in the PA Is Dependent
on A2AAR and A2BAR Activation. In preconstricted PA
rings isolated from WT mice, NECA (a nonselective AR
agonist) produced a concentration-dependent relaxation, sug-
gesting a role for either the A2AAR or A2BAR, since both ARs
are associated with vascular relaxation. Preincubation with
either the A2AAR antagonist SCH-58261 or A2BAR antagonist
CVT-6883 significantly decreased the NECA-mediated re-
laxation (Fig. 1A). Furthermore, PAs isolated from A2AAR
KO mice exhibited a decreased relaxation response to NECA
(EC50 –5.88 6 0.10 in WT versus –5.40 6 0.17 in A2AAR KO
mice, P , 0.05) (Fig. 1B). Incubation of PAs isolated from
A2AAR KO mice with the A2BAR antagonist abolished the
NECA-mediated vasorelaxation (Fig. 1B). Contrary to A2AAR
KO mice, PAs isolated from A2BAR KO mice exhibited an
increase in sensitivity to NECA compared with PAs from WT
mice (–5.88 6 0.10 versus –6.50 6 0.15, P , 0.05) (Fig. 1C).
Incubation of PAs isolated from A2BAR KO mice with the
A2AAR antagonist abolished the NECA-mediated vasorelax-
ation (Fig. 1C). Furthermore, genetic deletion of both the
A2AAR and A2BAR resulted in the absence of vasodilation in
response to increased NECA concentrations (Fig. 1D). Taken
together, our data suggest that both the A2AAR and A2BAR
contribute to relaxation in the PA.
Neither A1AR Nor A3AR Activation Resulted in
Vasoconstriction in the PA. Activation of either A1AR or
A3AR is known to result in vasoconstriction. Cumulative
addition of CCPA (an A1AR agonist) or Cl-IBMECA (an
A3AR agonist) did not cause vasoconstriction in PAs isolated
from WT mice. Furthermore, both CCPA and Cl-IBEMCA
caused vasorelaxation of PAs at high concentrations (1026 M
and 1025 M), possibly owing to nonselectivity of the agonists;
however, the vasodilatory response to CCPA and Cl-IBMECA
was significantly lower in comparison with that elicited by
NECA (Fig. 2).
Neither A1AR nor A3AR is Required for AR-Mediated
Vasorelaxation. Since A1AR or A3AR agonists were shown
to activate either the A2AAR or A2BAR at high concentrations,
we used PAs isolated from A2A/A2BAR DKO mice (Fig. 3). In
preconstricted PAs isolated from A2A/A2BAR DKO mice,
NECA did not affect the vascular relaxation, whereas both
CCPA and Cl-BMECA caused dilation at the highest dose
(1025 M) (Fig. 3A). Incubation of PAs isolated fromA2A/A2BAR
DKO mice with both the A1AR antagonist DPCPX and the
A3AR antagonist MRS-1593 did not affect CCPA- and Cl-
BMECA-mediated relaxation at the 1025 M concentration,
suggesting that the dilation mediated by CCPA and Cl-
BMECA at the 1025 M concentration is not dependent on
ARs (Fig. 3, B and C).
Genetic Deletion of A2AAR or A2BAR Resulted in
Decreased Endothelium-Mediated Vasorelaxation. Re-
cently, adenosine was described as an EDHF owing to its ability
Fig. 1. Adenosine receptor (AR)-medi-
ated relaxation in the pudendal artery
(PA) is mediated through activation of
both the A2AAR and A2BAR. (A) NECA
induced a concentration- dependent re-
laxation, and treatment with either an
A2AAR antagonist (SCH-58261; 1 mM) or
A2BAR antagonist (CVT-6883; 1 mM)
resulted in a decrease in NECA-mediated
vasorelaxation. (B) Genetic deletion of the
A2AAR resulted in a decrease in NECA-
mediated relaxation compared with wild
type (WT), and treatment with an A2BAR
antagonist (CVT-6883) completely abol-
ished the NECA response. (C) Genetic
deletion of the A2BAR resulted in signifi-
cantly altered NECA-mediated relaxation
compared with WT, and treatment with
an A2AAR antagonist (SCH-58261) abol-
ished the NECA response. (D) In A2A/
A2BAR DKO mice, the vasorelaxation re-
sponse to the adenosine receptor agonist
NECA was completely abolished. Data are
represented as mean 6 S.E.M. (N = 5–7).
*P , 0.05 versus WT and #P , 0.05 versus
corresponding KO (A2AAR KO or A2BAR
KO).
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to relax and hyperpolarize VSMCs. To test the effect of either
A2AAR or A2BAR deletion on the endothelium-mediated di-
lation, increased concentration of ACh resulted in a concentra-
tion- dependent relaxation in PAs isolated fromWT, A2AARKO,
and A2BAR KO mice (Fig. 4A). However, PAs isolated from A2A
KO or A2B KOmice exhibited a decrease in EC50 in response to
ACh compared with WT mice: EC50 –7.78 6 0.06 in WT versus
–7.296 0.06 in A2A KO, P, 0.05; and EC50 –7.786 0.06 in WT
versus –7.26 6 0.10 in A2B KO, P , 0.05 (Fig. 4B). Taken
together, our data suggest that both the A2AAR and A2BARmay
play a role in the endothelium-mediated relaxation.
Mechanism of A2AAR- and A2BAR-Mediated Relaxa-
tion in the PA. To look at the mechanisms of A2AAR-
mediated relaxation, we used PAs isolated from A2B KO
mice (Fig. 5A). Preincubation with either an NOS inhibitor
(L-NAME), protein kinase A inhibitor (KT 5720), or potas-
sium channel inhibition (5 mM KCl) significantly decreased
A2A-mediated vasorelaxation in PAs isolated from A2A KO
mice. To elucidate the mechanisms of A2BAR-mediated re-
laxation, we used PAs isolated from A2A KO mice (Fig. 5B).
Pretreatment with the either L-NAME or increased extracel-
lular K1 significantly decreased the A2B-mediated vasorelax-
ation, whereas treatment with KT 5720 did not affect
relaxation in PAs isolated from A2A KO mice. Taken together,
our data suggest that both A2AAR- and A2BAR-mediated
vasorelaxation requires activation of NO and K1 channels;
however, only the A2AAR-mediated response requires PKA
activation.
Message RNA Expression of ARs in the PA. In support
of our observations made in the functional studies, semi-
quantitative real-time PCR was used to determine mRNA
expression of the AR subtypes in PAs isolated from WT mice.
Of the four AR subtypes, only the A1R, A2AAR, and A2BAR
were expressed, with the A2AAR having the highest mRNA
expression level compared with the A1R and A2BAR (Fig. 6).
Discussion
Using pharmacological and genetic approaches, our study is
the first to investigate transcriptional expression and to
characterize the contribution of the four AR subtypes to
Fig. 2. A1AR and A3AR agonists caused vasorelaxation in PAs isolated
from WT mice. A CRC to NECA, CCPA, and Cl-IBMECA was performed
in PAs isolated from WT mice. Data are represented as mean 6 S.E.M.
(N = 5–7). *P , 0.05 versus NECA.
Fig. 3. Neither A1AR nor A3AR is required for the AR-mediated vasorelaxation in PAs. (A) CRC to NECA, CCPA and Cl-IBMECA in A2A/A2BAR DKO
mice. (B) CRC to CCPA in A2A/A2BAR DKO mice in the presence of vehicle or the A1AR antagonist DPCPX (0.1 mM) and the A3AR antagonist MRS1523
(1 mM). (C) CRC to Cl-IBMECA in A2A/A2BAR DKOmice in the presence of vehicle or DPCPX and MRS1523. Data are represented as mean6 S.E.M.
(N = 5–8). *P , 0.05 versus NECA.
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vascular tone regulation of the PA. Herein, we showed that: 1)
of the four AR subtypes, only the A1R, A2AAR, andA2BARwere
expressed in the PA; 2) although the A1AR was expressed in
the PA, only the A2AAR and A2BAR played a role in vascular
tone regulation of the PA; and 3) both A2AAR- and A2BAR-
mediated vasorelaxation requires activation of NOS and K1
channels; however, only A2AAR-mediated responses requires
PKA activation. In this paper, we sought to fill a gap in the
understanding of AR signaling in erectile function and define
the roles of AR subtypes in prepenile vascular tone regulation.
Numerous studies have investigated the contribution of
adenosine to erectile function, looking at the effect of AR
activation in the CC. However, this study is the first to
characterize the contribution of ARs in the regulation of PA
vascular tone, the major artery supplying and controlling
blood flow to the penis (Manabe et al., 2000; Hale et al., 2009).
In the first set of experiments, we observed that the adenosine
analog NECA caused a concentration-dependent vasorelaxa-
tion in murine PAs. As we already know, A2AAR and A2BAR
activation results in vasorelaxation, whereas A1AR and A3AR
activation results in vasoconstriction. In this study, our
results suggested that NECA-induced relaxation is mediated
through A2AAR and A2BAR activation. Indeed, preincubation
of PA rings with specific A2AAR (SCH-58261) or A2BAR
(CVT-6883) antagonists significantly decreased the NECA-
mediated relaxation, suggesting that both A2AAR and
A2BAR activation are required for the response to NECA in
PAs (Fig. 1A). Furthermore, PAs isolated from A2A KO mice
exhibited a decreased relaxation to NECA, which was
abolished using an A2BAR antagonist. Contrary to A2A KO
mice, PAs isolated from A2B KO mice exhibited an increase in
sensitivity to NECA compared with PAs from WT mice;
however, when incubated with an A2AAR antagonist, the
relaxation response to NECA was completely abolished. The
difference in PA responses using pharmacological inhibition,
compared with other genetic KO models, can be explained by
the fact that global gene deletion usually results in compen-
satory upregulation of other genes or other compensatory
signaling pathways. Regarding A2A and A2B ARs, although it
has been shown that a single gene KO results in upregulation
of the other AR in mesenteric artery (Teng et al., 2013), this
was not the case in aorta, where KO of A2AAR gene did not
affect the expression of A2BAR (Ponnoth et al., 2009). This also
confirms the importance of pharmacological studies in addi-
tion to studies using gene deletion. In addition, the differences
in the affinity of the receptors to the agonist could also explain
the different response toNECA in the PA isolated from theKO
mice, since A2BAR possesses the lowest affinity for adenosine
and NECA. Our results were confirmed using PAs isolated
from A2A/A2BAR DKO mice, where NECA failed to cause
vasorelaxation in the PA rings. Our data confirm the
important role played by both the A2AAR and A2BAR in CC
relaxation and, thus, erection. In fact, several studies
reported the role of both the A2AAR and A2BAR in mediating
CC vasorelaxation (Filippi et al., 2000; Noto et al., 2001; Faria
et al., 2006; Tostes et al., 2007). In mice, a recent study using a
genetic approach by Mi and colleagues (2008) showed high
Fig. 5. Both A2AAR- and A2BAR-mediated vasorelaxation is dependent on
nitric oxide (NO) in PAs. (A) Treatment with a nitric oxide synthase (NOS)
inhibitor (L-NAME; 100 mM), increased K+ (5 mM KCl), or with a protein
kinase A (PKA) inhibitor (KT 5720; 0.1 mM) significantly decreased
A2AAR-mediated vasorelaxation from A2BAR KO mice. (B) Treatment
with the either the NOS inhibitor or increased K+ significantly decreased
the A2BAR-mediated vasorelaxation, whereas treatment with KT 5720
(0.1 mM) did not affect relaxation in A2AAR KOmice. Data are represented
as mean 6 S.E.M. (N = 4–7). *P , 0.05 L-NAME versus vehicle, #P , 0.05
K+ versus vehicle and ¥P , 0.05 KT5720 versus vehicle.
Fig. 4. Genetic deletion of either the A2AAR or A2BAR resulted in
decreased sensitivity of the PA to endothelium-mediated relaxation. (A)
A2AAR KO and A2BAR KO mice exhibit decreases in ACh-mediated
relaxation (*P , 0.05 A2A KO versus WT and
#P , 0.05 A2B KO versus
WT). (B) Representative graph of EC50 (expressed as potency or pD2) from
both A2AAR KO and A2BAR KO mice exhibited a decrease in EC50 (*P ,
0.05 KOs versus WT). Data are represented as mean 6 S.E.M. (N = 5–7).
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A2BAR expression in the CC compared with expression of the
A2AAR. They also showed that vasorelaxation of the CC is
mediated solely through the activation of the A2BAR, whereas
the A2AAR did not seem to play a role. However, Tostes et al.
(2007) showed that both A2AAR antagonist SCH-58261 and
A2BAR antagonist MRS-1706 resulted in decreased CC re-
laxation to the nonspecific agonist 2-chloroadenosine, with the
combination of both antagonists resulting in almost total
inhibition of the CC’s relaxation, supporting our data in the
present study, whereas both the A2AAR and A2BAR contribute
to relaxation of the CC. In addition, other groups also have
shown the contribution of the A2AAR to vasorelaxation in the
CC (Mantelli et al., 1995; Filippi et al., 2000; Noto et al., 2001;
Faria et al., 2006; Moura et al., 2015).
A1AR and A3AR activation has been shown to mediate
vascular contraction (Ansari et al., 2007; El-Awady et al.,
2011; Kunduri et al., 2013). To test the contribution of the
A1AR and A3AR in the regulation of PA vascular tone, we
performed CRCs to both an A1AR agonist (CCPA) and A3AR
agonist (Cl-IBMECA). Both agonists failed to mediate vaso-
constriction in PAs, suggesting that neither A1AR nor A3AR
contribute to the vascular tone in PAs. However, both drugs at
high concentrations caused PA relaxation. These results were
not surprising, as both drugs at high concentrations activate
other receptors, including A2AAR and A2BAR (Teng and
Mustafa, 2011). To further rule out the role of A1AR and
A3AR, we performed the CRC to an A1AR agonist (CCPA)
and A3AR agonist (Cl-IBMECA) in PAs isolated from
A2A/A2BAR DKOmice. To our surprise, both agonists (CCPA
and Cl-IBMECA) were able to mediate vasorelaxation in PAs
from A2A/A2BAR DKO mice at high concentrations (10
25 M;
Fig. 3A). Preincubation of PAs isolated from A2A/A2BAR DKO
mice with both A1R and A3AR antagonists (DPCPX and
MRS1523, respectively) did not affect vasorelaxationmediated
by either CCPA or Cl-IBMECA at 1025 M, suggesting that
relaxations to both CCPA and Cl-IBMECA are not mediated by
AR activation and may be attributable to nonspecific agonist
effects (Fig. 3, B and C).
Recently, adenosine was described as an EDHF, with CD73
as an EDHF synthase, owing to its ability to relax and
hyperpolarize VSMCs (Ohta et al., 2013). We looked at the
effect of the genetic deletion of either A2AAR or A2BAR on
endothelium-mediated vasorelaxation in PAs. CRCs to ACh in
PAs isolated fromA2AARKOandA2BARKOmice resulted in a
rightward shift of CRC in A2AAR KO and A2BAR KOmice and
decreased sensitivity to ACh compared with WT mice, sug-
gesting that both receptors may play a role in endothelium-
mediated relaxation (Fig. 4, A and B). Our data suggest that
the A2AAR KO and A2BAR KO partially contributed to the
endothelium-mediated vasorelaxation in the PA, corroborat-
ing the role of adenosine as an EDHF.
Next, we sought to elucidate themechanism of AR-mediated
relaxation in the PA. To dissect the signaling pathways for
A2AR-mediated relaxation, we used PAs isolated from A2BAR
KO mice to study A2AAR-mediated relaxation and A2AAR KO
mice to study A2BAR-mediated relaxation in the PA (Fig. 5).
Previous studies suggested a role for PKA, the NO signaling
pathway, and potassium (K1) channels in mediating
adenosine-mediated vasorelaxation (Mi et al., 2008; Sanjani
et al., 2011; El-Gowelli et al., 2013; Hein et al., 2013). Our data
showed that PKA inhibition caused a rightward shift of the
CRC, resulting in a decrease in relaxation to NECA. In
addition, inhibition of NOS and increasing extracellular K1
resulted in a decrease in NECA-mediated vasorelaxation in
PAs (Fig. 5A). Our data suggest that A2AAR-mediated re-
laxation in the PA is dependent on PKA, NO, and K1 channel
activation. On the other hand, we found that A2BAR-mediated
relaxation in the PA is dependent on NO and K1 channel
activation, but not PKA, as PKA inhibition did not result in
decreased NECA-mediated vasorelaxation in PAs isolated
from A2AAR KO mice. In fact, a recent study showed that
A2BAR contributed to penile erection via an alternative
signaling pathway, which is dependent on PI3K/AKT signal-
ing (Wen et al., 2011b).
Several studies have looked at the contribution of adenosine
to erectile function both in vivo and in vitro. However, limited
studies have tried to characterize AR expression in the erectile
system. Using qPCR, Mi et al. (2008) demonstrated that the
A2BAR is the predominant receptor, with relatively low
expression of the A2AAR, whereas mRNA levels of both the
A1AR and A3AR were nondetectable in CC smooth muscle
cells. A similar pattern of AR expression was found in another
study using primary CC fibroblast cells (Wen et al., 2011b).
However, the expression level of ARs at the whole tissue level
or other cell types in the CC (i.e., endothelial cells) was not
evaluated. In the present study, we used isolated PAs to
evaluate the expression pattern of AR subtypes using qPCR.
We found that A1AR, A2AAR, and A2BAR were expressed in
PAs (with higher expression of A2AAR compared with A1AR
and A2BAR), whereas A3AR mRNA levels were not detectable
(Fig. 6). These results are in accordance with our functional
data in the case of A2AAR and A2BAR; however, it did not
translate to vascular response in the case of A1AR, where
there was a lack of response to the A1AR agonist CCPA (Fig.
3B). Although unexpected, this was not surprising, as previous
studies also showed a lack of A2AAR-mediated vascular
response despite the presence of this receptor in rat and
mouse mesenteric arteries (Rubino et al., 1995; Teng et al.,
2013). In addition, one limitation of the present study is that,
whereas the mRNA levels are important to determine, it was
difficult to assess the protein expression and level owing to the
size of the tissue, which would be more functionally relevant.
Although A1AR activation did not affect vascular reactivity,
A1ARmay still contribute to the overall PA vascular tone, as it
was shown to play an important role in the release of
neurotransmitters (Chiang et al., 1994; Ning et al., 2012). As
Fig. 6. Messenger RNA expression of A1, A2A, A2B, and A3 AR subtypes as
determined by real-time reverse-transcriptase PCR using total RNA
extracted fromWTmouse PAs. Valueswere normalized by the corresponding
18S ribosomal RNA of each sample. Results are represented as mean6 S.E.
M. (N = 7), with each N representing pooled PAs from seven to nine mice.
*P , 0.05.
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in recent studies using CC smooth muscle cells and CC
fibroblast cells, we were unable to detect A3AR expression in
the PA, suggesting that A3AR may not play an important role
in erectile function (Mi et al., 2008; Wen et al., 2010).
Early studies looked at the potential role of adenosine
signaling in erectile function at the level of the penile tissue;
however, our study is the first one to look at its role in the
regulation of PA vascular tone, which is an important
regulator of blood flow to the penis. Decreased adenosine
levels or signaling results in erectile dysfunction (ED),
whereas increased adenosine levels and signaling through
the A2BAR are associated with priapism (Mi et al., 2008; Wen
et al., 2011a). The use of adenosine as treatment of ED has
been previously evaluated; however, the rapid degradation of
adenosine may interfere with its ability to maintain erection
(Chiang et al., 1994; Kilic et al., 1994).
WenandXia (2012) suggestedA2BARactivation as apotential
therapeutic pathway for ED; however, further studies looking
at the change of AR expression in diseases associated with
vasculogenicED, such as hypertension anddiabetes, are crucial.
In fact, using an angiotensin II model of hypertension, the same
group demonstrated that in thismodel, whichwas also shown to
be associated with ED, A2BAR expression and signaling in-
creased in the kidney, resulting in progression of hypertension
associated with increased renal fibrosis (Jin et al., 2008; Labazi
et al., 2013; Zhang et al., 2013). Increased A2BAR signaling in
hypertension together with its association with penile fibrosis
will make the use of A2BAR agonist as a potential therapeutic
target for ED, at least in this model, counterproductive. An
alternative therapeutic target could be the use of an A2AAR
agonist, since our study showed that both A2AAR and A2BAR
signaling contributed to the regulation of PA vascular tone, in
addition to studies showing the involvement of A2AAR signal-
ing in mediating human CC relaxation. Furthermore, a recent
study demonstrated a synergic effect of a novel A2AAR agonist
and sildenafil (a PDE5 inhibitor), suggesting that combined
treatment may reduce side effects and increase efficacy in ED
patients who do not respond to sildenafil alone (Moura et al.,
2015). Together, A2AARactivationmay represent an alternative
clinical target for the treatment of ED, although future studies
looking at the change of AR expression and signaling in diseases
associated with vasculogenic ED would be critical to evaluate
the safety and efficacy of A2AAR agonists use in ED treatment.
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